RECRUITINGINTERVENTIONAL
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
About This Trial
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
Who May Be Eligible (Plain English)
Who May Qualify:
- Patient aged \>18
- Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
- Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
- Patient who has given informed, written and express consent,
- Patient affiliated with a French health insurance scheme.
Who Should NOT Join This Trial:
- Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
- Patient who will not have surgery
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Patient under guardianship, curatorship or safeguarding of justice,
- Pregnant and/or nursing patient,
- Patient with a history of other cancers within 5 years/10 years prior to inclusion
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patient aged \>18
* Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
* Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
* Patient who has given informed, written and express consent,
* Patient affiliated with a French health insurance scheme.
Exclusion Criteria:
* Early-stage disease (FIGO \<IIIB) or presence of extraperitoneal metastases,
* Patient who will not have surgery
* Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
* Patient under guardianship, curatorship or safeguarding of justice,
* Pregnant and/or nursing patient,
* Patient with a history of other cancers within 5 years/10 years prior to inclusion
Treatments Being Tested
BIOLOGICAL
Blood sample and tissue sample
During the surgery : * Tissus sample : primary tumor and metastasis * blood sample : 3 EDTA tubes * ex vivo MRI data
Locations (1)
NOUGARET Stephanie
Montpellier, France